BRAF and melanoma: Vemurafenib (Zelboraf®) and Dabrafenib (Tafinlar®) are available small-molecule inhibitors targeting the BRAF V600E mutation, demonstrating significantly improved overall survival rates without similar efficacy against the wild-type melanomas [11,12,13,14].